The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: A comparative study

Modern Pathology

Volumn 19, Issue 1, 2006, Pages 34-48

  Ordóñez, Nelson G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

D2 40; Electron microscopy; Immunohistochemistry; Mesothelioma; Podoplanin; Serous carcinoma

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN; CALRETININ; CD15 ANTIGEN; KERATIN; MONOCLONAL ANTIBODY B.72.3; MONOCLONAL ANTIBODY BER EP4; MONOCLONAL ANTIBODY BG 8; MONOCLONAL ANTIBODY D2 40; MONOCLONAL ANTIBODY MOC 31; PODOPLANIN; THROMBOMODULIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ELECTRON MICROSCOPY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; MESOTHELIUM CELL; OVARY CARCINOMA; PERITONEUM MESOTHELIOMA; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIGENS, CD15; ANTIGENS, NEOPLASM; CA-19-9 ANTIGEN; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CYSTADENOCARCINOMA, SEROUS; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MALE; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MICROSCOPY, ELECTRON; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; THROMBOMODULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 32844472809     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800471     Document Type: Article

References (74)

1. Attanoos RL, Webb R, Dojcinov SD, et al. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 2002;40:237-244.
2. Ordóñez NG. Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 1998;22:1203-1214.
3. Leers MPG, Aarts MMJ, Theunissen PHMH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998;32:209-216.
4. Ordóñez NG. Value of E-cadherin and N-cadherin immunostaining in the diagnosis of mesothelioma. Hum Pathol 2003;34:749-755.
5. Ordóñez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606.
6. Peralta-Soler A, Knudsen KA, Jaurand MC, et al. The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. Hum Pathol 1995;26:1363-1369.
7. Ordóñez NG. The diagnostic utility of immunohistochemistry in distinguishing between mesothelioma and renal cell carcinoma: a comparative study. Hum Pathol 2004;35:697-710.
8. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: as assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-347.
9. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;27:1031-1051.
10. Cury PM, Butcher DN, Fisher C, et al. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000;13:107-112.
11. Ordóñez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003;16:192-197.
12. y, in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989;135:931-937.
13. Riera JR, Astengo-Osuna C, Longmate JA, et al. The immunohistochemical diagnostic panel for epithelial mesothelioma. A reevaluation after heat-induced epitope retrieval. Am J Surg Pathol 1997;21:1409-1419.
14. Ordóñez NG. Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003;27:1418-1428.
15. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992;16:259-268.
16. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol 2002;15:434-440.
17. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-1257.
18. Breiteneder-Geleff S, Soleiman A, Horvat R, et al. Podoplanin - a specific marker for lymphatic endothelium expressed in angiosarcoma. Verh Deut Gesell Pathol 1999;83:270-275.
19. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154:385-394.
20. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18:105-110.
21. Sienko A, Zander DS, Killen D, et al. D2-40 is a novel new marker of malignant mesothelioma (MM): tissue microarray study of 45 MM versus 409 lung carcinomas and primary non-mesothelial neoplasms of the pleura and chest wall. Mod Pathol 2005;18(Suppl 1):318A.
22. Kimura N, Kimura I. Podoplanin as a marker for mesothelioma. Pathol Int 2005;55:83-86.
23. Raju U, Fine G, Greenawald KA, et al. Primary papillary serous neoplasia of the peritoneum: a clinicopathologic and ultrastructural study of eight cases. Hum Pathol 1989;20:426-436.
24. Warhol MJ, Hunter NJ, Corson JM. An ultrastructural comparison of mesotheliomas and adenocarcinomas of the ovary and endometrium. Int J Gynecol Pathol 1982;1:125-134.
25. Churg A, Roggli V, Galateau-Salle F, et al. Mesothelioma. In: Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (eds). World Health Organization Classification of Tumours Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon, France, 2004;128-136.
26. Ordóñez NG. Value of antibodies 44-3A6, SM3, HBME-1 and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. Am J Surg Pathol 1997;21:1399-1408.
27. Bollinger DJ, Wick MR, Dehner LP, et al. Peritoneal malignant mesothelioma versus serous papillary adenocarcinoma: a histochemical and immunohistochemical comparison. Am J Surg Pathol 1989;13:659-670.
28. Khoury N, Raju U, Crissman JD, et al. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas. Hum Pathol 1990;21:811-819.
29. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999;80:569-578.
30. Breiteneder-Geleff S, Matsui K, Soleiman A, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997;151:1141-1152.
31. Sassetti C, Tangemann K, Singer MS, et al. Identification of podocalyxin-like protein as a high endothelial venule ligand for L-selectin: parallels to CD34. J Exp Med 1998;187:1965-1975.
32. Birner P, Schindl M, Obermair A, et al. Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. Int J Cancer (Pred Oncol) 2001;95:29-33.
33. Sinzelle E, Duong Van Huyen JP, Breiteneder-Geleff S, et al. Intrapericardial lymphangioma with podoplanin immunohistochemical characterization of lymphatic endothelial cells. Histopathology 2000;37:93-94.
34. Doglioni C, Dei Tos AP, Laurino L, et al. Calretinin: a novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-1046.
35. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001;25:43-50.
36. Ordóñez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 1998;11:929-933.
37. Cathro HP, Stoler MH. The utility of calretinin, inhibin, and WT1 immunohistochemical staining in the differential diagnosis of ovarian tumors. Hum Pathol 2005;36:195-201.
38. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 1997;31:140-143.
39. Ordónez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215-1221.
40. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003;443:122-132.
41. Brown RW, Clark GM, Tandon AK, et al. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum Pathol 1993;24:347-354.
42. Collins CL, Ordóñez NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 1992;141:827-833.
43. Ordóñez NG. Value of thrombomodulin immunostaining in the diagnosis of mesothelioma. Histopathology 1997;31:25-30.
44. Attanoos RL, Appleton MAC, Goddard H, et al. Thrombomodulin expression in malignant peritoneal mesothelioma and serous papillary adenocarcinoma of the ovary. J Pathol 1995;176:S49A.
45. Edwards C, Oates J. OV632 and MOC-31 in the diagnosis of mesothelioma and adenocarcinoma: an assessment of their use in formalin-fixed paraffin wax embedded material. J Clin Pathol 1995;48:626-630.
46. Ordóñez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 1998;29:166-169.
47. Latza U, Niedobitek G, Schwarting R, et al. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 1990;43:213-219.
48. Ordóñez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma: the MD Anderson experience and a critical review of the literature. Am J Clin Pathol 1998;109:85-89.
49. Maguire B, Whitaker D, Carrello S, et al. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens. Diagn Cytopathol 1994;10:130-134.
50. Rothacker D, Möbius G. Varieties of serous surface papillary carcinoma of the peritoneum in northern Germany: a thirty-year autopsy study. Int J Gynecol Pathol 1995;14:310-318.
51. Cherchi PL, Marras V, Capobianco G, et al. Immunohistochemical evaluation of a new epithelial antigen, Ber-EP4, in ovarian cancer: preliminary results. Eur J Gynaec Oncol 2001;22:433-435.
52. Lafebvre MP, Rodriguez F, Schlom J, et al. The application of a monoclonal antibody to the differentiation of benign and malignant mesothelial proliferations from adenocarcinomas (abstract). Lab Invest 1985;52:38A.
53. Warnock ML, Stoloff A, Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma. Periodic acid-Schiff, monoclonal antibodies B72.3, and Leu M1. Am J Pathol 1988;133:30-38.
54. Thor A, Gorstein F, Ohuchi N, et al. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. JNCI 1986;76:995-1006.
55. Wick MR, Mills SE, Dehner LP, et al. Serous papillary carcinomas arising from the peritoneum and ovaries: a clinicopathologic and immunohistochemical comparison. Int J Gynecol Pathol 1989;8:179-188.
56. Wick MR, Mills SE, Swanson PE. Expression of 'myelomonocytic' antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces. Am J Clin Pathol 1990;94:18-26.
57. Sheibani K, Battifora H, Burke JS, et al. Leu-M1 antigen in human neoplasms: an immunohistologic study of 400 cases. Am J Surg Pathol 1986;10:227-236.
58. González-Lois C, Ballentín C, Sotelo MT, et al. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura. Histopathology 2001;38:528-534.
59. Gaffey MJ, Mills SE, Swanson PE, et al. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surg Pathol 1992;16:593-599.
60. Magnani JL, Steplewski Z, Koprowski H, et al. Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 1983;43:5489-5492.
61. Lagendijk JH, Mullink H, Van Diest PJ, et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol 1998;29:491-497.
62. Ordóñez NG, Freedman RS, Herlyn M. Lewis and related tumor-associated determinants on ovarian carcinoma. Gynecol Oncol 1987;26:1-10.
63. Oshio G, Yamaki K, Imamura T, et al. Distribution of the carbohydrate antigens, DU-PAN-2 and CA19-9, in tumors of the lung. Tumori 1995;81:67-73.
64. Chenard-Neu MP, Bellocq JP, Maier A, et al. Mésothéliomes malins de la plévre. Analyse de leurs aspects immunohistochemiques. Ann Pathol 1990;10:20-27.
65. Coleman M, Henderson DW, Mukherjee TM. The ultrastructural pathology of malignant pleural mesothelioma. Part I. Pathol Ann 1989;24:303-353.
66. Dardick I, Jabi M, McCaughey WTE, et al. Diffuse epithelial mesothelioma: a review of the ultrastructural spectrum. Ultrastruct Pathol 1987;11:503-533.
67. Oury TD, Hammar SP, Roggli VL. Ultrastructural features of diffuse malignant mesotheliomas. Hum Pathol 1998;29:1382-1392.
68. Blaustein A. Papillary serous tumors of the ovary: an electron microscopic study. Gynecol Oncol 1976;4:314-323.
69. Gondos B. Electron microscopic study of papillary serous tumors of the ovary. Cancer 1971;27:1455-1464.
70. Roberts DK, Marshall RB, Wharton JT. Ultrastructure of ovarian tumors. I. Papillary serous cystadenocarcinoma. Cancer 1970;25:947-958.
71. Ferenczy A. Electron microscopy of histologically difficult to diagnose gynecologic neoplasms. Ultrastruct Pathol 1987;11:335-360.
72. Gooneratne S, Sassone M, Blaustein A, et al. Serous surface papillary carcinoma of the ovary: a clinicopathologic study of 16 cases. Int J Gynecol Pathol 1982;1:258-269.
73. Dumke K, Schnoy N, Specht G, et al. Comparative light and electron microscopic studies of cystic and papillary tumors of the peritoneum. Virchows Arch (Pathol Anat) 1983;399:25-39.
74. Torikata C, Kawai T, Nakayama M. Confronting cisternae and ciliated cells in malignant pleural mesothelioma: an ultrastructural study. Ultrastruct Pathol 1991;15:249-256.